Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

Uncovering Genetic Rescue and Functional Rebalancing in Telomeropathies Through Genome Editing and High-Resolution Screening

Objectif

Telomere dysfunction can result in cells being eliminated by apoptosis, entering senescence, or undergoing malignant transformation. Symptoms associated with telomeropathies include bone marrow failure, idiopathic pulmonary fibrosis, liver disease, and defects of the immune system, skin, eyes, and skeleton. Patients with telomeropathies are typically managed based on their clinical presentation. Treatment options for various manifestations may include growth factor support, bone marrow transplantation, antifibrotic medications, or organ transplantation. All these approaches improve the symptoms of specific sequelae rather than treating the biological cause of the disease. We propose that by intervening at its inception and “rebalancing” or restoring telomere function we may ameliorate the disease process.
The overarching hypothesis of our proposed research is that by defining disease-associated cell phenotype regulators, i.e. “rebalancing factors”, and the complete compendium of disease-causing alleles, we will elucidate the underlying biology of these conditions and potentially a path to therapy. To test this hypothesis, we need to identify genes that can rescue telomere dysfunction, define the mechanistic basis of rebalancing, and define the functional impact of all genetic variants linked to telomeropathies. To accomplish these objectives, we will i) use nanoseq sequencing to examine somatic genetic rescue in tissues from unique telomeropathy patient cohorts, ii) investigate how the rebalancing factors we identify influence cell behaviour and telomere homeostasis in cell and animal models, and iii) use saturation prime editing combined with functional screens to systematically assess the phenotypes associated with all possible variants in genes linked to telomeropathies. As a result of this work, we hope to revolutionise our understanding of telomeropathies and help patients live longer and healthier lives.

Champ scientifique (EuroSciVoc)

Ce projet n'a pas encore été classé par EuroSciVoc.
Proposez les domaines scientifiques qui vous semblent les plus pertinents et aidez-nous à améliorer notre service de classification.

Mots‑clés

Programme(s)

Thème(s)

Régime de financement

HORIZON-ERC - HORIZON ERC Grants

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) ERC-2025-ADG

Voir tous les projets financés au titre de cet appel

Institution d’accueil

GENOME RESEARCH LIMITED LBG
Contribution nette de l'UE
€ 2 496 154,00
Adresse
WELLCOME SANGER INSTITUTE WELLCOME GENOME CAMPUS HINXTON
CB10 1SA SAFFRON WALDEN
Royaume-Uni
Région
East of England East Anglia Cambridgeshire CC
Type d’activité
Research Organisations
Liens
Coût total
Aucune donnée

Bénéficiaires (1)